Is Regenerative Medicine FDA-Approved? Understanding FDA Approval vs. Tennessee Law

If you are researching regenerative medicine, you may encounter statements that seem reassuring but are not always easy to interpret:

“FDA registered.”

“Manufactured in an FDA-registered facility.”

“Available under Tennessee law.”

“FDA compliant.”

And sometimes simply: “FDA-approved.”



Those phrases do not all mean the same thing.

Regenerative medicine is a broad field that includes very different products and therapies, each with its own regulatory status. At the same time, Tennessee recently enacted a new law addressing certain stem cell and regenerative medicine therapies that have not been approved by the U.S. Food and Drug Administration.

So can regenerative medicine be FDA-approved?

The most accurate answer is: FDA approval depends on the specific product and the specific use.

Understanding that distinction can help patients ask better questions and avoid assuming that one regulatory term means something it does not.

First, What Does “FDA-Approved” Actually Mean?

FDA approval is not a general stamp placed on an entire type of medicine.

Approval generally applies to a specific medical product for a specific indication or use after the FDA has reviewed the applicable evidence and regulatory submission.

That means asking, “Is regenerative medicine FDA-approved?” is a little like asking whether “medication” is FDA-approved.

Some medications are. Others are not.

The same principle applies when talking about cellular, biologic, or regenerative products.

The FDA maintains a list of approved cellular and gene therapy products, which includes a number of licensed therapies used for specific medical indications.

But that does not mean every therapy described as “regenerative medicine,” “stem cell therapy,” “cellular therapy,” or an “orthobiologic” has received FDA approval.

What About Stem Cell Therapies?

This is where patients should pay especially close attention to terminology.

The FDA states that stem cell products are regulated by the agency and that, generally, stem cell products require FDA approval.

According to the FDA’s consumer guidance, the stem cell products it identifies as FDA-approved are blood-forming stem cells derived from umbilical cord blood. Those products are approved for certain disorders involving the body's blood-forming system, not as general treatments for musculoskeletal pain or orthopedic conditions. That distinction matters.

A product involving cells from umbilical cord tissue, Wharton’s jelly, adipose tissue, or another source should not automatically be assumed to have the same FDA status simply because another type of cellular product has received approval.

Are Regenerative Medicine Therapies FDA-Approved for Orthopedic Conditions?

Patients often encounter regenerative medicine while researching problems involving the knees, back, shoulders, hips, tendons, or joints.

The FDA’s current patient information specifically states that regenerative medicine therapies have not been approved to treat orthopedic conditions such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.

This is an especially important point for patients exploring regenerative therapies for musculoskeletal concerns.

The fact that a therapy may be discussed, researched, or available under a particular state framework does not mean the FDA has approved that therapy for an orthopedic diagnosis.

What About Exosomes?

Exosomes are another term patients increasingly encounter when researching regenerative medicine.

The FDA states that exosome products intended to treat diseases or conditions generally require FDA approval and that there are currently no FDA-approved exosome products.

Patients should therefore be cautious about assuming that an exosome product is FDA-approved because it is manufactured by a particular company, comes from a registered facility, or is available through a medical provider.

Those are separate regulatory questions.

“FDA Registered” Is Not the Same as “FDA-Approved”

This may be one of the most useful distinctions for patients to understand.

A manufacturer or facility may be required to register with the FDA.

That registration does not mean the FDA has approved the facility's products.

The FDA addressed this distinction again in 2026, explaining that it does not “approve” healthcare providers and that registration of an establishment or listing of a product does not itself indicate FDA approval or mean that the product can legally be marketed for every proposed use.

So when you hear: “This product comes from an FDA-registered facility.”

That may provide useful information about the manufacturer or facility, but it does not answer the question: “Has this specific therapy been FDA-approved for my condition?”

Those are two separate questions.

What Does Tennessee’s New Law Change?

This is where the distinction between state medical practice law and federal FDA regulation becomes especially important.

In 2026, Tennessee enacted HB 2246, which became Public Chapter 1016.

The law authorizes a Tennessee physician to perform certain stem cell or regenerative medicine therapies that are not approved by the FDA when the therapy is used for a treatment or procedure within the physician’s scope of practice and the requirements of the Tennessee law are satisfied. The legislation took effect in 2026.

Notice the wording:

The Tennessee statute specifically contemplates therapies that have not received FDA approval.

That means Tennessee authorization and FDA approval cannot be treated as interchangeable concepts.

Does Tennessee Law Make a Therapy FDA-Approved?

No.

A state legislature cannot grant FDA approval to a medical product.

Tennessee’s law establishes a state framework governing qualifying physicians and therapies. It does not change the federal approval status of the product being used.

The FDA continues to regulate regenerative medicine products under federal law, while Tennessee regulates aspects of medical practice within the state.

Both frameworks can therefore be relevant at the same time.

A treatment may fall within Tennessee’s statutory framework while still being an unapproved product or an unapproved use under the federal regulatory framework.

That is why patients should be told clearly which regulatory status applies.

Tennessee’s Law Includes Patient Protections

HB 2246 does more than establish that qualifying therapies may be performed.

The law also creates requirements involving the products being used and the manner in which qualifying therapies are provided.

For certain regenerative medicine products, Tennessee requires documentation that can include lot-specific sterility information and a certificate of analysis. The statute also addresses manufacturer documentation for cellular products, Wharton’s jelly products, and exosome-based products.

Physicians practicing under the framework must also obtain written informed consent, and the law establishes requirements for reporting adverse events associated with qualifying therapies.

These requirements are important.

But none of them should be interpreted as FDA approval.

A certificate of analysis is not FDA approval.

Facility registration is not FDA approval.

Third-party accreditation is not FDA approval.

Compliance with Tennessee law is not FDA approval.

Each describes something different.

Why This Distinction Matters for Patients

Regulatory terminology can create a sense of certainty that may not actually exist.

Imagine that a patient hears:

“This product is manufactured in an FDA-registered facility.”

Without additional context, the patient might reasonably interpret that statement as meaning the FDA has evaluated and approved the treatment.

That is not necessarily true.

Likewise, saying a therapy is “legal in Tennessee” does not tell a patient whether the therapy has been FDA-approved, what evidence supports its use for that patient's condition, or how likely it is to help.

Patients deserve all of those distinctions.

Questions to Ask a Regenerative Medicine Provider

Before considering an emerging regenerative therapy, ask specific questions instead of relying on broad labels.

What exactly is being administered?

Ask for the actual type of product or therapy rather than simply accepting the term “regenerative medicine.”

Is this specific therapy FDA-approved for my condition?

The words “for my condition” matter.

FDA approval can be indication-specific.

Are you saying the product is FDA-approved or that the facility is FDA-registered?

These are very different statements.

What does the certificate of analysis tell us?

If a certificate of analysis is available, ask what information it contains and what it does—and does not, establish.

What evidence supports using this therapy for someone with my diagnosis?

Availability and evidence are not the same thing.

What are the known and potential risks?

Emerging treatments should receive the same risk-benefit discussion as more established therapies.

What alternatives should I consider?

Patients should understand other reasonable options, including conservative treatment, rehabilitation, medications, established procedures, surgical evaluation when appropriate, or choosing not to undergo a procedure.

Be Careful With Regulatory-Sounding Marketing Language

Patients researching regenerative medicine should be cautious when marketing relies heavily on phrases such as:

• FDA registered
• FDA listed
• FDA compliant
• Manufactured in an FDA-registered facility
• Physician administered
• Meets Tennessee requirements

Any of those statements may describe a legitimate characteristic.

But none, standing alone, means:

“The FDA has reviewed and approved this therapy for your medical condition.”

The FDA itself warns that registration and listing should not be confused with approval.

A provider should be willing to explain the difference clearly.

How We Approach These Conversations at True Wellness

At True Wellness Integrated Medicine, we believe emerging therapies require more transparency, not less.

Patients should understand what is being considered, why it is being considered, what its regulatory status is, what evidence is available, what uncertainties remain, and what other options may be appropriate.

Regenerative medicine should not begin with a promise.

It should begin with a diagnosis and a medical conversation.

For some patients, an emerging treatment may deserve consideration as part of a broader plan. For others, a different approach may be more appropriate.

The objective should always be to match the care plan to the patient rather than beginning with a treatment and trying to make every patient fit it.

The Bottom Line: FDA Approval and Tennessee Law Are Two Different Questions

The most important takeaway is simple:

Something being permitted under Tennessee law does not mean it is FDA-approved.

Likewise, a manufacturer being registered with the FDA does not mean the FDA has approved every product the manufacturer produces.

When considering regenerative medicine, patients should ask about the specific therapy, specific product, specific medical use, available evidence, risks, alternatives, and regulatory status.

Those questions provide much more useful information than any broad marketing label.

Tennessee’s new law has created a clearer state framework for certain therapies, but it has not eliminated the need for careful patient education.

If anything, it makes understanding these distinctions even more important.

Learn More

For a deeper look at Tennessee’s new framework, read:

Tennessee’s New Regenerative Medicine Law: What Patients Should Know About HB 2246

You can also visit our Regenerative Medicine in Chattanooga patient education page for an overview of regenerative medicine, medical evaluation, product transparency, and questions to consider before treatment.

If you are experiencing an ongoing musculoskeletal concern, the True Wellness Integrated Medicine team can evaluate the underlying problem and discuss the range of treatment options that may be appropriate for your individual situation.

Tennessee-Required Notice

THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW. This physician performs one (1) or more stem cell or regenerative medicine therapies that have not yet been approved by the United States food and drug administration. You are encouraged to consult with your primary care provider before undergoing any stem cell or regenerative medicine therapy.

This article is provided for general educational purposes and does not constitute medical or legal advice. Regulatory status can vary by product and intended use, and patients should discuss their individual circumstances with an appropriate healthcare professional.